Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse MKT  >  CEL-SCI Corporation    

 SummaryNewsCalendarCompanyFinancialsRevisions 
Financials ($)
Sales 2016 1,00 M
EBIT 2016 -37,1 M
Net income 2016 -
Debt 2016 -
Yield 2016 -
Sales 2017 -
EBIT 2017 -
Net income 2017 -
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017 -
Capi. / Sales 2016 75,3x
Capi. / Sales 2017 -
Capitalization 75,3 M
More Financials
Company
CEL-SCI Corp. is a biotechnology company, which is involved in the research and development of investigational immunotherapy products for the treatment of cancer and infectious diseases.The company's lead investigational therapy, Multikine is currently in a pivotal phase 3 clinical trial against... 
More about the company
Latest news on CEL-SCI CORPORATION
05/02 CEL SCI : NEW STORY CEL-SCI Reports Record Monthly Patient Enrollment in April f..
05/02 CEL SCI : Reports Record Monthly Patient Enrollment in April for Its Phase 3 Hea..
04/14 CEL-SCI CORPORATION : CEL-SCI's Manufacturing of Cancer Killer Multikine Marks a..
04/13 CEL-SCI CORPORATION : (NYSE MKT: CVM) is Selected as Bob Flaherty's Personal Pic..
04/08 CEL SCI : NEW STORY CEL-SCI Featured on The RedChip Money Report Airing on Newsm..
04/08 CEL SCI : Featured on The RedChip Money Report Airing on Newsmax TV
04/01 CEL SCI : NEW STORY CEL-SCI Reports Monthly Patient Enrollment in March for Its ..
04/01 CEL SCI : Reports Monthly Patient Enrollment in March for Its Phase 3 Head and N..
More news
Sector news : Bio Therapeutic Drugs
08:10p Sanofi sees 'strong strategic' fit with U.S. Medivation
05:56p Levi & Korsinsky, LLP Announces Investigation as to Whether the Sale of IMS H..
03:15pINCYTE CORPORATION : quaterly earnings release
More sector news : Bio Therapeutic Drugs
Comments 
Advertisement
Income Statement Evolution
More Financials